Proton Therapy Systems Market Size, Trends, Share, Growth, and Regional Forecast, 2026 - 2033

The global proton therapy systems market size is estimated to grow from US$ 1.2 billion in 2026 to US$ 2.2 billion by 2033. The market is projected to record a CAGR of 9.0% from 2026 to 2033.

The proton therapy systems industry is expanding steadily, driven by rising cancer incidence, demand for precision radiotherapy, and increasing adoption of advanced oncology technologies. North America leads due to strong infrastructure, skilled specialists, and favorable reimbursement. At the same time, the Asia Pacific region grows fastest, driven by improving healthcare access, rising awareness, and accelerating investments in proton therapy centers.

• Dominant Segment: Multi-room proton therapy systems lead with a 61.3% share in 2025, driven by strong adoption in high-throughput cancer centers, which offer broad clinical capabilities, advanced imaging integration, and cost-efficiency compared to single-room systems.
• Dominant Region: North America leads due to advanced oncology infrastructure, strong reimbursement, rising cancer cases, and early technology adoption, while Asia Pacific expands fastest with increasing investments and new proton therapy centers.
• Market Drivers: Growth is driven by rising global cancer burden, demand for precise tumor targeting, technological innovations in beam delivery, and expanding hospital investments in next-generation radiotherapy systems.
• Market Opportunity: Major opportunities include compact proton systems, lower-cost solutions, growing adoption in emerging markets, pediatric oncology demand, and partnerships for improved imaging, planning, and dosimetry technologies.

Driver - Growing Preference for Targeted, Less Toxic Treatment

A growing global shift toward targeted, less toxic cancer treatment is a major driver of the proton therapy systems market. Proton therapy precisely deposits radiation within the tumor with minimal exit dose, significantly reducing harm to surrounding tissues compared to conventional photon therapy. Clinical evidence shows strong benefits: in a study of 1,483 adults receiving chemoradiation, only 11.5% of patients treated with proton therapy experienced severe grade-3 or higher toxicities requiring hospitalization, compared with 27.6% treated with photon therapy. In head-and-neck cancer, a meta-analysis of more than 3,000 patients found that proton therapy significantly reduced acute side effects such as mucositis, pain, dysphagia, and weight loss, while also improving 1-year, 2-year, and 5-year overall survival. These measurable reductions in treatment-related toxicity, paired with better quality of life and enhanced long-term safety, especially for pediatric and elderly patients, are increasing physician preference and accelerating global adoption of proton therapy systems.

Restraints - High Installation and Operating Costs

High installation and operating costs remain one of the strongest restraints on the proton therapy systems market. Establishing a proton therapy center typically requires an initial investment of $50 million to over $200 million, depending on the number of treatment rooms and the scale of infrastructure. Even newer compact single-room systems often cost $40–50 million, making them inaccessible for many mid-sized hospitals. These high costs stem from the need for advanced particle accelerators, radiation-shielded bunkers with thick concrete walls, high-capacity power and cooling systems, and precision imaging and safety technologies. Operating expenses further limit the adoption of proton centers, which require highly specialized physicists, engineers, and radiation oncologists, and overall running costs can be 3–4 times higher than conventional photon radiotherapy units. Maintenance of cyclotrons or synchrotrons adds additional recurring costs. For many healthcare systems, especially in developing regions, these substantial financial requirements delay investment decisions, restrict facility expansion, and reduce patient access to proton therapy.

Opportunity - Expansion of Compact and Single-Room Proton Systems

The expansion of compact and single-room proton systems presents a significant growth opportunity for the proton therapy systems market. Traditional multi-room proton centers are expensive and require extensive space, often exceeding $100 million in construction costs. In contrast, newer compact single-room systems cost $30–50 million and require far less space, making them feasible for mid-sized hospitals and urban cancer centers. These systems can be installed in existing radiation oncology facilities, reducing construction time and capital expenditure while increasing geographic access to proton therapy. As of 2025, several compact systems have already been delivered and commissioned at major centers worldwide, reflecting growing adoption. By enabling more hospitals to offer proton therapy, compact systems expand treatment capacity, reduce patient travel burdens, and improve access in emerging markets. This trend supports broader adoption, especially for pediatric and complex cancer cases, and strengthens the market’s overall growth potential globally.

By Setup Type Insights

Multi-Room Systems occupies 66.1% share of the global market in 2025, due to their ability to treat multiple patients simultaneously, offering high throughput and operational efficiency. These systems are ideal for large hospitals and academic cancer centers that manage high patient volumes, justifying their substantial installation and infrastructure costs. As of 2024, multi-room setups accounted for the largest market share and are projected to maintain over 75% of the market through 2034. Their design allows integration of advanced imaging, adaptive therapy, and complex treatment protocols across several treatment rooms, maximizing utilization and revenue potential. While single-room compact systems are growing, multi-room facilities remain preferred for major oncology centers seeking scale, capacity, and long-term operational efficiency, making them the dominant segment in the proton therapy systems market globally.

By Indication Insights

Brain and central nervous system (CNS) cancers dominate the market, with a 44.6% share in 2025, due to their high clinical complexity and the need for precise treatment. Globally, approximately 321,624 new brain and CNS cancer cases were diagnosed in 2022, with an age-standardized incidence rate of about 3.5 per 100,000 people. These tumors are often located near critical structures such as the optic nerves, hearing centers, and endocrine glands, requiring highly targeted radiation to minimize long-term neurological damage. Proton therapy’s precise dose deposition, stopping at the tumor site, spares surrounding healthy brain tissue, reducing risks of cognitive deficits, vision or hearing loss, hormonal dysfunction, and secondary malignancies.

North America Proton Therapy Systems Market Trends

North America dominates the proton therapy systems market with a 40.8% share in 2025, driven by extensive infrastructure, high technology adoption, and strong clinical demand. As of 2024–2025, the region accounted for approximately 42–49% of the global market share. The U.S. alone operates around 43–46 proton therapy centers with over 110 treatment rooms, providing widespread access to advanced radiotherapy. High cancer incidence further fuels demand, with nearly 1.9 million new cancer cases reported in 2021. The region benefits from a skilled oncology workforce, advanced hospital facilities, and supportive insurance and reimbursement policies, making proton therapy financially feasible for many centers. These factors collectively enable North America to lead in both adoption and capacity, maintaining its dominance while supporting ongoing technological advancements and high patient throughput in the global proton therapy landscape.

Europe Proton Therapy Systems Market Trends

Europe is a key region in the proton therapy systems market due to its expanding healthcare infrastructure and growing demand for cancer care. As of 2020, Europe had over 30 operational proton therapy centers, accounting for roughly 30% of global facilities, up from 15 in 2017. Major centers are located in Germany, France, the UK, and Italy, supporting widespread access to advanced radiotherapy. Europe reports approximately 3.2 million new cancer cases annually, with nearly half of patients receiving radiotherapy at least once, highlighting the need for precise treatment options like proton therapy. Collaborative initiatives such as the European Particle Therapy Network (EPTN) promote clinical research, standardization, and data sharing, enhancing adoption and innovation. These factors make Europe a strategic market for proton therapy expansion and technological advancement.

Asia Pacific Proton Therapy Systems Market Trends

Asia Pacific is the fastest-growing region in the proton therapy systems market, driven by its high cancer burden and expanding healthcare infrastructure. The region accounts for nearly 50% of global cancer cases, with approximately 9.6 million new cases reported in 2020. Despite this, radiotherapy capacity is limited, with only about 44% of the required megavoltage machines available to meet patient demand. Countries such as Japan, China, South Korea, and India are rapidly investing in advanced oncology infrastructure, including proton therapy centers, to bridge this gap. Rising awareness of precision radiotherapy, government support, and private hospital investments further accelerate adoption. The combination of a large patient population, unmet treatment needs, and increasing infrastructure makes the Asia Pacific the fastest-growing market for proton therapy systems globally.

Leading companies in the proton therapy systems market focus on advanced system design, multi-room and compact solutions, and safety standards. They invest in R&D, staff training, and innovative technologies, collaborating with hospitals to enhance treatment precision, reduce side effects, and expand global adoption, meeting the growing demand for advanced, targeted cancer radiotherapy.

Key Industry Developments:

• In November 2025, Carilion Clinic, in partnership with Mevion Medical Systems, announced plans to introduce proton therapy services to Southwest Virginia. The initiative aimed to expand access to advanced, precise cancer treatments in the region, providing patients with state-of-the-art radiotherapy options closer to home.
• In September 2025, the University of Tsukuba Hospital began treating patients with its second proton therapy system, enhancing its capacity to provide advanced, precise cancer care. The new system allows the hospital to serve more patients and expand its proton therapy services.
• In July 2025, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital established a new proton therapy facility, aiming to enhance advanced cancer treatment. The center announced that the facility is scheduled to begin operations in fiscal year 2030, expanding access to precision radiotherapy for patients in the region.